Edge's Aneurysm Drug Cuts Hospital Stays, Improves Outcomes
This article was originally published in Scrip
Executive Summary
Edge Therapeutics Inc. reported on Feb. 19 during the International Stroke Conference (ISC) in Los Angeles on that EG-1962 cut 3.5 days from time spent in the intensive care unit (ICU) and doubled the likelihood of favorable outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH).
You may also be interested in...
Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize
Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.